Abstract 14482: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major clinical outcomes. Methods: Using the TriNetX Research network, we identified patients initiating GLP1RA and DPP4i with T2DM, aged ≥18 years, excluding type 1 diabetes. Propensity score matching (1:1) balanced the cohorts. Index date was the first prescription of the respective drug class. Outcomes were assessed from 1 day to 1,825 days (5 years) post-index using risk analysis, Kaplan-Meier survival, and number-of-instances methods, excluding patients with the outcome prior to the time window. Results: After matching, GLP1RA use was associated with substantially lower risk of several key outcomes compared to DPP4i. All-cause mortality was markedly reduced (5.6% vs 10.4%; risk ratio 0.536, 95% CI 0.526-0.545; HR 0.474, 95% CI 0.465-0.483; log-rank p<0.001), with 5-year survival of 90.83% vs 82.83%.Cardiovascular benefits included lower myocardial infarction (3.2% vs 3.6%; risk ratio 0.894; HR 0.793), cerebral infarction (3.0% vs 3.5%; risk ratio 0.872; HR 0.777), heart failure (survival HR 0.882), and cardiac arrest (0.8% vs 1.3%; risk ratio 0.609; HR 0.542). Renal outcomes showed lower acute kidney injury (8.5% vs 9.4%; risk ratio 0.911; HR 0.815) and chronic kidney disease (11.6% vs 12.2%; risk ratio 0.957; HR 0.851). Ophthalmic complications (6.4% vs 4.6%) and polyneuropathy (7.6% vs 5.3%) were higher with GLP1RA. Conclusions: In this large propensity score-matched real-world cohort of patients with T2DM, GLP1RA initiation was associated with substantially lower all-cause mortality, reduced cardiovascular events, and better renal outcomes compared to DPP4i over 5 years, supporting the preferential use of GLP1RA in appropriate patients.